(444 days)
The S Dispensing Line is intended for transfer of liquid drug from bag to syringes through the APOTECAsyringe automated system. The device is used inside an automatic system APOTEC Asyringe that tightens the tube with the syringe, while the connection with the bag is done manually. The transfer of liquid takes place by depression through the mechanical action on the piston of the syringe of a manipulator equipped with a gripping device.
Sdispensinglineisadevice for the transferofiquids, with the purpose of preparation of in drugs. The device is intended to be used with APOTECAsyringe automatic compoundingsystem. Thedeviceissingleuse, sterilizedbyEOandsingle-packagedinablister. The device is not manufactured with natural rubber latex. Medical grade plastics are used, according to ISO 10993 series standards. Sdispensingline is a non-vented infusion setused as a connecting part be rock syringe without hypodermic needle. The tip in contact with the syringe must perfectly by means of a pressure connector (not by screwind). in ordertoavoidloss ofmedication; the connectoris to be assembled atthe endof the line. The short line enables the transfer of drug from a bag to a luer lock syringe through the APOTECAsyringe automated system. The line is intended for the connection of the spike perforator; a check valve prevents the flow back towards thebag.
The provided text describes the regulatory clearance for the "S dispensing line" device, which is an intravascular administration set. The information focuses on non-clinical performance testing to demonstrate substantial equivalence to predicate devices, rather than clinical studies involving human patients or complex algorithms.
Therefore, many of the requested categories for acceptance criteria and study details (e.g., sample size for test set, data provenance, number of experts, adjudication method, MRMC study, training set ground truth) are not applicable as they pertain to clinical or AI algorithm performance, which was not the basis for this regulatory submission.
Here's a breakdown of the available information:
1. Table of Acceptance Criteria and Reported Device Performance
| Performance Characteristic | Acceptance Criteria/Standard | Reported Device Performance |
|---|---|---|
| Performance Testing | ||
| Right connection/absence of ruptures between syringe tip and connector after 100 usages | Right connection/absence of ruptures between syringe tip and connector after 100 usages | Right connection, no ruptures |
| Absence of leakage during filling after 100 usages | Absence of leakage during filling after 100 usages | No leakage |
| Right disconnection/absence of ruptures between syringe tip and connector after 100 usages | Right disconnection/absence of ruptures between syringe tip and connector after 100 usages | Right disconnection, no ruptures |
| Absence of spilling after the disconnection | Absence of spilling after the disconnection | No spilling |
| Performance testing after real aging (ongoing) | No change in performances after 3 years | Results of ongoing real aging study not provided, but implies satisfactory performance based on 3-year shelf life claims and completed accelerated aging study. |
| Test for particulate contamination | ISO 8536-4:2010 | Implied compliance with ISO 8536-4:2010, as demonstrated by favorable outcome of testing for substantial equivalence. |
| Test for leakage | ISO 8536-4:2010 | Implied compliance with ISO 8536-4:2010, as demonstrated by favorable outcome of testing for substantial equivalence. |
| Test for tensile strength | ISO 8536-4:2010 | Implied compliance with ISO 8536-4:2010, as demonstrated by favorable outcome of testing for substantial equivalence. |
| Test for the closure-piercing device | ISO 8536-4:2010 | Implied compliance with ISO 8536-4:2010, as demonstrated by favorable outcome of testing for substantial equivalence. |
| Test for transparency | ISO 8536-4:2010 | Implied compliance with ISO 8536-4:2010, as demonstrated by favorable outcome of testing for substantial equivalence. |
| Biocompatibility Testing | ||
| Cytotoxicity MEM | ISO 10993-5:2009, ISO 10993-12:2012 | Implied compliance with ISO 10993-5:2009, ISO 10993-12:2012. |
| Elution test | No specific standard listed in the table, but falls under biocompatibility. Implied satisfactory results. | Implied satisfactory results for elution test. |
| Sensitization (Guinea Pig Sensitization Test) | ISO 10993-10:2010, ISO 10993-12:2012 | Implied compliance with ISO 10993-10:2010, ISO 10993-12:2012. |
| Irritation or Intracutaneous Reactivity (Rabbit Intracutaneous reactivity) | ISO 10993-10:2010, ISO 10993-12:2012 | Implied compliance with ISO 10993-10:2010, ISO 10993-12:2012. |
| Acute Systemic Toxicity | ISO 10993-11:2017, ISO 10993-12:2012 | Implied compliance with ISO 10993-11:2017, ISO 10993-12:2012. |
| Material-Mediated Pyrogenicity (Pyrogen Test (USP Rabbit Test)) | USP 41-NF36:2018 <151> Pyrogen Test (USP Rabbit Test) | Implied compliance with USP 41-NF36:2018 <151>. |
| Hemocompatibility (Haemolysis test indirect contact) | ISO 10993-4:2017, ISO 10993-12:2012 | Implied compliance with ISO 10993-4:2017, ISO 10993-12:2012. |
| Particulate matters testing | USP 788 | Implied compliance with USP 788. |
| Sterilization and Shelf Life | ||
| Sterilization Validation | ISO 11135:2014 | Implied compliance with ISO 11135:2014. |
| Packaging Validation | Effective microbiological barrier, product sterility and integrity preservation | Implied satisfactory results, indicating effective microbiological barrier and product integrity preservation. |
| Shelf life - 3 years | Sterility and product integrity maintained over the entire shelf life / Sterility and product integrity maintained over 3 year shelf life | Accelerated Ageing Study completed, 3 year Real Time Study (Ongoing). The completion of the accelerated study and the ongoing real-time study with the stated acceptance criteria indicate performance for 3-year shelf life. |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Sample Size: Not explicitly stated for performance or biocompatibility tests. The "100 usages" for connection/disconnection/leakage tests indicates a sample of 100 operations for these specific tests. Other tests likely followed the sample size requirements dictated by the respective ISO standards.
- Data Provenance: Not specified. These are non-clinical bench and lab tests.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
- Not Applicable. Ground truth, in this context, refers to a clinical diagnosis or outcome, typically established by medical experts for AI/clinical studies. This submission is for a physical medical device and relies on engineering and laboratory testing protocols against established international standards.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
- Not Applicable. Adjudication methods are typically used in clinical studies or for establishing ground truth in image interpretation/AI algorithm development where human reviewers may disagree. This is a non-clinical device clearance.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- Not Applicable. This is a non-clinical submission for a physical medical device (intravascular administration set), not an AI algorithm or a diagnostic tool requiring human reader studies.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- Not Applicable. This is a physical medical device; there is no algorithm involved.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
- The "ground truth" for this device's performance is based on objective measurements and assessments against established engineering and biocompatibility standards (e.g., ISO 8536-4:2010, ISO 10993 series, USP standards). For specific tests like "Right connection/absence of ruptures," the ground truth is a direct observation of the device's physical integrity and functional performance under defined conditions.
8. The sample size for the training set
- Not Applicable. There is no "training set" as this is not an AI/machine learning device.
9. How the ground truth for the training set was established
- Not Applicable. There is no "training set" as this is not an AI/machine learning device.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo in blue, with the words "U.S. FOOD & DRUG" stacked on top of the word "ADMINISTRATION".
December 17, 2020
AEA srl Michele Mengoni Quality & Regulatory via Fiume 16 Angeli di Rosora, 60030 It
Re: K192770
Trade/Device Name: S dispensing line Regulation Number: 21 CFR 880.5440 Regulation Name: Intravascular administration set Regulatory Class: Class II Product Code: LHI Dated: December 10, 2020 Received: December 16, 2020
Dear Michele Mengoni:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
{1}------------------------------------------------
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
CAPT Alan Stevens Acting Director DHT3C: Division of Drug Delivery and General Hospital Devices. and Human Factors OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K192770
Device Name S Dispensing Line
Indications for Use (Describe)
The S Dispensing Line is intended for transfer of liquid drug from bag to syringes through the APOTECAsyringe automated system. The device is used inside an automatic system APOTEC Asyringe that tightens the tube with the syringe, while the connection with the bag is done manually. The transfer of liquid takes place by depression through the mechanical action on the piston of the syringe of a manipulator equipped with a gripping device.
| Type of Use (Select one or both, as applicable) |
|---|
| ☒ Prescription Use (Part 21 CFR 801 Subpart D) |
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
Image /page/3/Picture/0 description: The image shows the word "LOCCIONI" in a bold, sans-serif font. The letters are all capitalized and are a dark red color. The background is white, which makes the text stand out.
510(k) Summary
Thefollowing510(k)summaryhasbeenpreparedpursuanttorequirementsspecifiedin21 CFR807.92.
I SUBMITTER
AEA SRL ViaFiume, 16AngelidiRosa60030AnconaItaly Phone: 0039-0731-816689 Contact Person: Michele Mengoni Date prepared: December 10th , 2020
II DEVICE
| TradeNames: | S dispensing line |
|---|---|
| CommonorUsualNames: | Intravascular administration set |
| Classification Names: | Set, IV Fluid Transfer |
| Regulation Numbers: | Sdispensingline: 880.5440-Intravascularadministrationset |
| Regulatory Class: | II |
| ProductCodes: | S dispensing line: LHI |
| PanelIdentification: | General Hospital |
III PREDICATE DEVICES
| S dispensing line | Predicate device | Predicate device |
|---|---|---|
| Trade Name: | Rapid-Fill™ Tubeset | Exacta-MixAdministration Set |
| 510(k) number: | K022523 | K002705 |
IV DEVICE DESCRIPTION
Sdispensinglineisadevice for the transferofiquids, with the purpose of preparation of in drugs. The device is intended to be used with APOTECAsyringe automatic compoundingsystem.
Thedeviceissingleuse, sterilizedbyEOandsingle-packagedinablister. The device is not manufactured with natural rubber latex.
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows the word "LOCCIONI" in a bold, sans-serif font. The color of the text is a dark red. The letters are evenly spaced and appear to be a logo or brand name.
Medical grade plastics are used, according to ISO 10993 series standards.
The device has the same intended use and the same technological characteristics as its predicate devices.
Sdispensingline is a non-vented infusion setused as a connecting part be rock syringe without hypodermic needle. The tip in contact with the syringe must perfectly by means of a pressure connector (not by screwind). in ordertoavoidloss ofmedication; the connectoris to be assembled atthe endof the line.
The short line enables the transfer of drug from a bag to a luer lock syringe through the APOTECAsyringe automated system.
The line is intended for the connection of the spike perforator; a check valve prevents the flow back towards thebag. Components and materials are reported in the following table.
| COMPONENT | MATERIAL |
|---|---|
| Vented spike with protective cap | ABS (vented spike), LDPE (protective cap), Polyethylene (vent) |
| Tubing | PVC D.E.H.P. Free |
| Check valve | Silicone (internal part), Acrylic (upper and lower parts) |
| Straight connector | ABS |
| Elbow connector | PVC D.E.H.P. Free |
| Female luer slip connector | Polycarbonate |
V INTENDED USE AND INDICATIONS FOR USE
The S dispensing line is intended for transfer of liquid drug from a bag to syringes through the APOTECAsyringe automated system.
The device is used inside an automatic system APOTECAsyringe that tightens the tube with the connection with the bagis done manually. The transfer of liquid takes place by depression through the piston of the syringe of a manipulator equipped with a gripping device.
VI comparison of technological characteristics with The Predicate devices
S dispensing line has the intended use and the same technological characteristics of its predicate devices:
- . The S dispensing line has the same intended use of the predicated devices (K022523 and K002705).
- The S dispensing line and the predicate devices (K022523 and K002705) component materials comply with ISO 10993 ● as applicable to the intended use of the device.
- The S dispensing line hasvery similar design and materials of predicated devices (K022523 and K002705). .
The differences between the predicate devices and the subject devices include:
- The proximal end connector of the S dispensing line has been appropriately designed to be managed by APOTECAsyringe . compoundingsystemandatthesametimetofitwiththeluerlockofthesyringe used inside the automaticsystem.
{5}------------------------------------------------
Image /page/5/Picture/0 description: The image shows the word "LOCCIONI" in a bold, sans-serif font. The letters are all capitalized and are a dark red color. The word appears to be a logo or brand name.
AEA srl Via Fiume 16,60030 Angelidi Rosora, AN (Italy) R.I. - C.F. - P. Iva 00686250424 info@loccioni.com
- The sterilization method for the proposed device S dispensing line is ethylene oxide whereas the sterilization method . for the predicate device is gamma irradiation.
The differences between proposed device and predicate devices do not raise any issues of safety and effectiveness.
VII. PERFORMANCE DATA
Non-Clinical Testing
AEA srl has performed non-clinicalion testing based on the risk analysis conducted, as summarized in the following tables. The favourable outcome of this testing demonstrates that the AEA proposed device performs in an equivalent manner to the predicate devices.
| Performance Characteristic | Acceptance Criteria/Standard | |
|---|---|---|
| Performance Testing Ref.Section 018"Performance Testing-Bench" | Right connection/absence ofruptures between syringe tip andconnector after 100 usages | Right connection, no ruptures |
| Absence of leakage during filling after100 usages | No leakage | |
| Right disconnection/absence ofruptures between syringe tip andconnector after 100 usages | Right disconnection, no ruptures | |
| Absenceofspillingafterthedisconnection | No spilling | |
| Performance testing after real aging(ongoing) | No change in performances after 3 years | |
| Test for particulate contamination | ISO 8536-4:2010 | |
| Test for leakage | ISO 8536-4:2010 | |
| Test for tensile strength | ISO 8536-4:2010 | |
| Test for the closure-piercing device | ISO 8536-4:2010 | |
| Test for transparency | ISO 8536-4:2010 | |
| Biocompatibility Testing Ref.Section 015"Biocompatibility" | Cytotoxicity MEM | ISO 10993-5:2009, ISO 10993-12:2012 |
| Elution test | ||
| Sensitization | ISO 10993-10:2010, ISO 10993-12:2012 |
{6}------------------------------------------------
Image /page/6/Picture/0 description: The image shows the word "LOCCIONI" in a bold, sans-serif font. The letters are all capitalized and are a dark red color. The background is white, which makes the text stand out.
AEA srl Via Fiume 16,60030 Angelidi Rosora, AN (Italy) R.I. - C.F. - P. Iva 00686250424 info@loccioni.com
| Performance Characteristic | Acceptance Criteria/Standard | |
|---|---|---|
| Guinea Pig Sensitization Test | ||
| Irritation or Intracutaneous ReactivityRabbit Intracutaneous reactivity | ISO 10993-10:2010, ISO 10993-12:2012 | |
| Acute Systemic Toxicity | ISO 10993-11:2017, ISO 10993-12:2012 | |
| Material-Mediated PyrogenicityPyrogen Test (USP Rabbit Test) | USP 41-NF36:2018 <151> Pyrogen Test(USP Rabbit Test) | |
| HemocompatibilityHaemolysis test indirect contact | ISO 10993-4:2017, ISO 10993-12:2012 | |
| Particulate matters testing | USP 788 | |
| Sterilization Validation | ISO 11135:2014 | |
| Sterilization and Shelf LifeRef. Section 014"Sterilization and Shelf Life" | Packaging Validation | Effective microbiological barrier, product sterility andintegrity preservation |
| Shelf life - 3 years | Sterility and product integrity maintained over theentire shelf life | |
| Sterility and product integrity maintained over 3 yearshelf life | ||
| 3 year Real Time Study (Ongoing)Accelerated Ageing Study completed |
Clinical Testing
Clinical testing was not required for this submission.
Substantial Equivalence
The S dispensing line is substantially equivalent to the predicate devices in intended use, principles of operation, technology, design, materials and performance.
VII CONCLUSION
Results of performance and biocompatibility testing conducted on the proposed devices demonstrate that the is substantially equivalent to the predicate devices.
§ 880.5860 Piston syringe.
(a)
Identification. A piston syringe is a device intended for medical purposes that consists of a calibrated hollow barrel and a movable plunger. At one end of the barrel there is a male connector (nozzle) for fitting the female connector (hub) of a hypodermic single lumen needle. The device is used to inject fluids into, or withdraw fluids from, the body.(b)
Classification. Class II (performance standards).